Sort
82,697 grants matching “vaccine development”
Adaptive and Innate Immunity, Memory and Repertoire in Vaccination and Infection
$4,104,239Mark M Davis · Stanford University · U19 · FY2017 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit
$4,102,856John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2014 · AI
UZ-UCSF CTU
$4,102,046Zvavahera Mike Chirenje · University Of California, San Francisco · UM1 · FY2021 · AI
Studies of Inherited Causes of Fungal Susceptability
$4,100,812Sergio Rosenzweig · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Penn Center for AIDS Research
$4,100,153Ronald G Collman · University Of Pennsylvania · P30 · FY2020 · AI
TUBERCULOSIS PREVENTION RESEARCH UNIT
$4,100,000Case Western Reserve University · N01 · FY2000 · AI
Immunobiology of Peanut Allergy and Its Treatment: A Prototype
$4,097,659Hugh Sampson · Icahn School Of Medicine At Mount Sinai · U19 · FY2008 · AI
Enhancing anti-tumor immunity in head and neck neoplasms
$4,097,112Clint Allen · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Development &Manufacture of an MDR Tuberculosis Vaccine
$4,095,564Infectious Disease Research Institute · UC1 · FY2005 · AI
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$4,095,431Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Advanced Development of Vaccines for Filoviruses
$4,095,421John Eldridge · Auro Vaccines Llc · N01 · FY2023 · AI
MALARIA VACCINE PRODUCTION &SUPPORT SERVICES
$4,092,900Science Applications International Corp · N01 · FY2000 · AI
DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS
$4,091,788Chris Fox · Access To Advanced Health Institute · N01 · FY2018 · AI
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
$4,091,472Joseph J. Eron · Univ Of North Carolina Chapel Hill · UM1 · FY2023 · AI
Assays to Support Development of Malaria Transmission Blocking Vaccines
$4,089,130Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2
$4,088,041Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research
$4,083,010Steven M Wolinsky · Northwestern University At Chicago · U01 · FY2021 · HL
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$4,077,456Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL
SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design
$4,076,804George M Shaw · University Of Pennsylvania · P01 · FY2024 · AI
Global innate immune responses to HIV-1 infection
$4,074,664John A T Young · Salk Institute For Biological Studies · P01 · FY2011 · AI
Dartmouth Clinical and Translational Science Institute
$4,073,191Steven L. Bernstein · Dartmouth-Hitchcock Clinic · UM1 · FY2024 · TR
Pandemic Influenza Translational Research and Novel Drug Therapy
$4,071,797Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Defects in Immunoregulatory Cell Receptors in Patients with LeukemiaLymphoma
$4,070,979Thomas A Waldmann · Clinical Sciences · Z01 · FY2007 · CA
Sexually Transmitted Infections Clinical Trials Group
$4,069,483Giudice Linda · University Of California, San Francisco · N01 · FY2012 · AI
Dartmouth Clinical and Translational Science Institute
$4,068,641Steven L. Bernstein · Dartmouth-Hitchcock Clinic · UM1 · FY2025 · TR